Catastrophic antiphospholipid syndrome

Journal of Intensive Care Medicine

Volumn 21, Issue 3, 2006, Pages 144-159

  Vora, Setu K ^a   Asherson, Ronald A ^b   Erkan, Doruk ^c,d  

^a Pulmonary Physicians of Norwich   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Anticardiolipin antibody; Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Critical care; Intensive care unit; Lupus anticoagulant; Multiple organ dysfunction syndrome; Thrombotic microangiopathy

Indexed keywords

ANCROD; ANTICOAGULANT AGENT; ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEFIBROTIDE; FIBRINOLYTIC AGENT; HEPARIN; HLA DM ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 1BETA; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; PROSTACYCLIN; PROSTAGLANDIN E1; PROTEIN C; PROTEIN S; PROTHROMBIN; RITUXIMAB; THROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WARFARIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTIFICIAL VENTILATION; CARDIOGENIC SHOCK; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; EARLY DIAGNOSIS; HEART FAILURE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE; LUNG INSUFFICIENCY; MALIGNANT HYPERTENSION; MULTIPLE ORGAN FAILURE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; STROKE; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ALGORITHMS; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ILLNESS; HUMANS;

EID: 33646522415     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066606287041     Document Type: Review

References (106)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19:508-512.
3. Piette JC, Cervera R, Levy RA, et al. The catastrophic antiphospholipid syndrome - Asherson's syndrome. Ann Med Interne (Paris). 2003;154:195-196.
4. Cervera R, Asherson RA. Multiorgan failure due to rapid occlusive vascular disease in antiphospholipid syndrome: the "catastrophic" antiphospholipid syndrome. APLAR J Rheumatol. 2004;7:254-262.
5. Westney GE, Harris EN. Catastrophic antiphospholipid syndrome in the intensive care unit. Crit Care Clin. 2002;18:805-817.
6. Erkan D, Lockshin MD. What is antiphospholipid syndrome? Curr Rheumatol Rep. 2004;6:451-457.
7. Rand JH. Molecular pathogenesis of antiphospholipid syndrome. Circ Res. 2002;90:29-37.
8. Blank M, Asherson RA, Cervera R, et al. Antiphospholipid syndrome infectious origin. J Clin Immunol. 2004;24:12-23.
9. Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome - molecular mimicry? J Rheumatol. 2000;27:12-14.
10. Cervera R, Asherson RA, Acevedo ML, et al. Antiphospholipid syndrome associated with infections: clinical and microbi logical characteristics of 100 patients. Ann Rheum Dis. 2004;63:1312-1317.
11. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine. 2001;80:355-377.
12. 2-glycoprotein-I) induces experimental APS in naive mice. J Autoimmun. 1994;7:441-447.
13. Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest. 2002;109:797-804.
14. Gharavi AE, Pierangeli SS, Espinola RG, et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 2002;46:545-552.
15. Petri M. Classification and epidemiology of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, et al, eds. The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Amsterdam: Elsevier; 2002:11-20.
16. de Groot PG, Horbach DA, Derksen RH. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus. 1996;5:488-493.
17. Wolberg AS, Roubey RA. Mechanisms of autoantibody-induced monocyte tissue factor expression. Thromb Res. 2004;114:391-396.
18. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood. 2003;101:3495-3500.
19. Sanchez ML, Katsumata K, Atsumi T, et al. Association of HLA-DM polymorphism with the production of antiphospholipid antibodies. Ann Rheum Dis. 2004;63:1645-1648.
20. Yasuda S, Atsumi T, Matsuura E, et al. Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant. Arthritis Rheum. 2005;52:212-218.
21. Sebastiani GD, Galeazzi M, Tincani A, et al. HLA-DPB1 alleles association of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus. 2003;12:560-563.
22. Hudson M, Herr AL, Rauch J, et al. The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol. 2003;30:2385-2391.
23. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost. 1997; 78:1-6.
24. Cervera R, Gómez-Puerta JA, Espinosa G, et al. "CAPS Registry": a review of 200 cases from the International Registry of patients with catastrophic antiphospholipid syndrome (CAPS) [abstract]. Ann Rheum Dis. 2003;62:88.
25. Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med. 1998;104:381-385.
26. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology. 2003;497-519.
27. Cervera R, Font J, Gomez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205-1209.
28. Espinosa G, Cervera R, Font J, et al. The lung in the antiphospholipid syndrome. Ann Rheum Dis. 2002;61:195-198.
29. Wiedermann FJ, Mayr A, Schobersberger W, et al. Acute respiratory failure associated with catastrophic antiphospholipid syndrome. J Intern Med. 2000;247:723-730.
30. Laterza OF, Nayer H, Jo Bill M, et al. Unusually high concentrations of cTnI and cTnT in a patient with catastrophic antiphospholipid antibody syndrome. Clin Chim Acta. 2003;337:173-176.
31. Gunnewiek JM, Van Der Hoeven JG. Cardiac troponin elevations among critically ill patients. Curr Opin Crit Care. 2004;10:342-346.
32. Zakynthinos EG, Vassilakopoulos T, Kontogianni DD, et al. A role for transoesophageal echocardiography in the early diagnosis of catastrophic antiphospholipid syndrome. J Intern Med. 2000;248:519-524.
33. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-534.
34. Wilson WA. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am. 2001;27:499-505.
35. Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol. 1989;16:614-617.
36. Asherson RA, Espinosa G, Cervera R, et al. Catastrophic antiphospholipid syndrome. Proposed guidelines for diagnosis and treatment. J Clin Rheumatol. 2002;8:157-165.
37. Wahl DG, De Maistre E, Guillemin F, et al. Antibodies against phospholipids and beta 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus. QJM. 1998;91:125-130.
38. Bick RL, Arun B, Frenkel EP. Antiphospholipid-thrombosis syndromes. Haemostasis. 1999;29:100-110.
39. Wenzel C, Stoiser B, Locker GJ, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med. 2002;30:763-770.
40. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730-736.
41. Amoura Z, Costedoat-Chalumeau N, Veyradier A, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum. 2004;50:3260-3264.
42. Karmochkine M, Mazoyer E, Marcelli A, et al. High prevalence of antiphospholipid antibodies in disseminated intravascular coagulation. Thromb Haemost. 1996;75:971.
43. Koenig M, Roy M, Baccot S, et al. Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheumatol. 2004;24:166-168.
44. Le Thi Thuong D, Tieulie N, Costedoat N, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis. 2005;64:273-278.
45. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003,31:1250-1256.
46. George JN, Gilcher RO, Smith JW, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and management. J Clin Apheresis. 1998;13:120-125.
47. Burns ER, Lou Y, Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol. 2004;75:18-21.
48. Smith OP, White B. Infectious purpura fulminans: diagnosis and treatment. Br J Haematol. 1990;104:202-207.
49. Betrosian AP, Balla M, Papanikolaou M, et al. Meningococcal purpura fulminans in a patient with systemic lupus erythematosus: a mimic for catastrophic antiphospholipid antibody syndrome? Am J Med Sci. 2004;327:373-375.
50. Campanelli A, Kaya G, Ozsahin AH, et al. Purpura fulminans in a child as a complication of chickenpox infection. Dermatology. 2004;208:262-264.
51. Cone LA, B Waterbor R, Sofonio MV. Purpura fulminans due to Streptococcus pneumoniae sepsis following gastric bypass. Obes Surg. 2004;14:690-694.
52. Deshmukh PM, Camp CJ, Rose FB, et al. Capnocytophaga canimorsus sepsis with purpura fulminans and symmetrical gangrene following a dog bite in a shelter employee. Am J Med Sci. 2004;327:369-372.
53. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):311S-337S.
54. Stanton PE Jr, Evans JR, Lefemine AA, et al. White clot syndrome. South Med J. 1988;81:616-620.
55. Martinuzzo ME, Forastiero RR, Adamczuk Y, et al. Antiplatelet factor 4 - heparin antibodies in patients with antiphospholipid antibodies. Thromb Res. 1999;95:271-279.
56. Gruel Y. Antiphospholipid syndrome and heparin-induced thrombocytopenia: update on similarities and differences. J Autoimmun. 2000;15:265-268.
57. Erkan D, Asherson RA, Cervera R, et al. Plasma exchange or intravenous immunoglobulins in catastrophic antiphospholipid syndrome. In: 7th International Lupus Congress Abstract Book. New York: 2004:M24A.
58. Amital H, Levy Y, Davidson C, et al. Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases. Semin Arthritis Rheum. 2001;31:127-132.
59. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301-1308.
60. Drakulovic MB, Torres A, Bauer TT, et al: Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: A randomised trial. Lancet. 1999;354:1851-1858.
61. Schweickert WD, Gehlbach BK, Pohlman AS, et al. Daily interruption of sedative infusions and complications of critical illness in mechanically ventilated patients. Crit Care Med. 2004;32:1272-1276.
62. Ely EW, Meade MO, Haponik EF, et al: Mechanical ventilator weaning protocols driven by nonphysician health-care professionals: Evidence-based clinical practice guidelines. Chest. 2001;120:454S-463S.
63. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest. 2004;114:1187-1195.
64. Cook DJ, Witt LG, Cook RJ, et al: Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med. 1991;91:519-527.
65. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-873.
66. Espinosa G, Cervera R, Font J, et al. Adrenal involvement in the antiphospholipid syndrome. Lupus. 2003;12:569-572.
67. Annane D. Time for a consensus definition of corticosteroid insufficiency in critically ill patients. Crit Care Med. 2003;31:1868-1869.
68. Erkan D, Asherson RA, Espinosa G, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003;62:530-533.
69. Erkan D, Leibowitz E, Berman J, et al. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol. 2002;29:843-849.
70. Burcoglu-O'Ral A, Erkan D, Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol. 2002;29:2006-2011.
71. Ehresmann S, Arkfeld D, Shinada S, et al. A novel therapeutic approach for catastrophic antiphospholipid syndrome (CAPS) when conventional therapy with anticoagulants and steroids were unsuccessful [abstract]. Ann Rheum Dis. 2004;64 (suppl):FR10278.
72. Ozaki M, Ogata M, Yokoyama T, et al. Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome. Can J Anaesth. 2005;52:143-147.
73. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):265S-286S.
74. Cowchock S. Prevention of fetal death in the antiphospholipid antibody syndrome. Lupus. 1996;5:467-472.
75. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10:1222-1226.
76. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.
77. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286-290.
78. Lasa M, Brook M, Saklatvala J, et al. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol. 2001;21:771-780.
79. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24:1131-1138.
80. Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum. 2003;48:3320-3327.
81. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43:1460-1480.
82. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology. 2000;39:421-426.
83. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci. 2004;25:306-310.
84. Chapman SA, Gilkerson KL, Davin TD, et al. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother. 2004;38:2059-2067.
85. Anonymous. FDA Interim Statement Regarding Immune Globulin Intravenous (IVIG). Washington, DC: FDA; 2002.
86. Erkan D, Asherson RA, Cervera R, et al. Reply to the "letter to the editor" by Jean et al (Intravenous immunoglobulins and antiphospholipid syndrome: comment on the article by Erkan et al). Arthritis Rheum. 2004;50:2711-2713.
87. Flamholz R, Tran T, Grad GI, et al. Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta (2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apheresis. 1999;14:171-176.
88. Wallace DJ. Apheresis for lupus erythematosus: state of the art. Lupus. 2001;10:193-196.
89. Kane D, McSweeney F, Swan N, et al. Catastrophic antiphospholipid antibody syndrome in primary systemic sclerosis. J Rheumatol. 1998;25:810-812.
90. Kovacs IB, Mayou SC, Kirby JD. Infusion of a stable prostacyclin analogue, iloprost, to patients with peripheral vascular disease: lack of antiplatelet effect but risk of thromboembolism. Am J Med. 1991;90:41-46.
91. Tedeschi A, Meroni PL, Del Papa N, et al. Thrombotic events in patients with systemic sclerosis treated with iloprost. Arthritis Rheum. 1998;41:559-560.
92. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154:1671-1677.
93. Dosekun AK, Pollak VE, Glas-Greenwalt P, et al. Ancrod in systemic lupus erythematosus with thrombosis. Clinical and fibrinolysis effects. Arch Intern Med. 1984;144:37-42.
94. Falanga A, Vignoli A, Marchetti M, et al. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia. 2003;17:1636-1642.
95. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, et al. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica. 2004;89: ECR34.
96. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138.
97. de Groot PG, Horbach DA, Derksen RH. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus. 1996;5:488-493.
98. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7:23-38.
99. Yan SB, Helterbrand JD, Hartman DL, et al: Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 2001;120:915-922.
100. Matthay MA, Ware LB. Plasma protein C levels in patients with acute lung injury: prognostic significance. Crit Care Med. 2004;32(5 suppl):S229-S232.
101. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human APC for severe sepsis. N Engl J Med. 2001;344:699-709.
102. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001;44:2870-2878.
103. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 2003;48:3272-3279.
104. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost. 2004;2:1558-1563.
105. Mullenix PS, Andersen CA, Starnes BW. Atherosclerosis as inflammation. Ann Vasc Surg. 2005;19:130-138.
106. Kinlay S, Schwartz GG, Olsson AG, et al. Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-1566.